Ocular Therapeutix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCUL research report →
Range $14 – $30
Price Chart
About the company
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions.
- CEO
- Pravin U. Dugel
- IPO
- 2014
- Employees
- 325
- HQ
- Bedford, MA, US
Get TickerSpark's AI analysis on OCUL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.23B
- P/E
- -4.12
- Fwd P/E
- 6.07
- PEG
- 2.68
- P/S
- 26.29
- P/B
- 3.08
- EV/EBITDA
- -2.83
- Div Yield
- 0.00%
- Gross Margin
- 87.32%
- Op Margin
- -680.90%
- Net Margin
- -648.64%
- ROE
- -59.50%
- ROIC
- -62.89%
Latest fiscal year · YoY change
- Revenue
- $51.82M-18.7%
- Gross Profit
- $45.25M-22.1%
- Op Income
- $-270,017,000
- Net Income
- $-265,939,000-37.4%
- EPS
- $-1.42-16.4%
- OCF Growth
- -52.1%
- FCF Growth
- -59.5%
- 52W High
- $16.44
- 52W Low
- $5.54
- 50D MA
- $7.59
- 200D MA
- $8.85
- Beta
- 0.99
- RSI (14)
- 31
- Avg Volume
- 3.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ocular Therapeutix said third-quarter 2026 was a transformational quarter, with AXPAXLI on track for a fourth-quarter NDA submission and a strengthened clinical and commercial case in wet AMD.· November 9, 2026
- NDA submission for AXPAXLI in wet AMD remains on track for the fourth quarter, supported by FDA alignment and a safety database expected to include more than 300 patients with at least 1 year of follow-up.
- SOL-R’s primary endpoint was moved from week 56 to week 40 to preserve trial integrity ahead of the planned interim safety unmasking; the company said the change carries only a minimal alpha penalty of 0.0001.
- Management emphasized SOL-1 post-hoc data showing durability, including approximately 70% of treated subjects remaining quantitatively dry through week 36 and about 2/3 rescue-free at 12 months in the difficult SOL-1 population.
- The company extended SOL-X dosing from every 24 weeks to every 48 weeks, saying this better reflects confidence that many patients may not need treatment every 6 months and could support annual maintenance dosing.
- Cash and cash equivalents were $530.6 million at quarter-end, with runway expected into 2028 based on current assumptions, excluding the full anticipated cost of commercialization.
Ocular Therapeutix did not provide revenue or EPS on this call. The company said it ended the third quarter with $530.6 million in cash and cash equivalents, and management expects that to fund operations into 2028 based on current assumptions, excluding the full anticipated expenses of commercializing AXPAXLI. On the clinical/regulatory side, management said the NDA for AXPAXLI in wet AMD remains planned for the fourth quarter, with the submission supported by SOL-1 week 52 efficacy data, SOL-1 and interim SOL-R week 52 safety data, and confirmatory evidence; the SOL-R primary endpoint is now week 40, and top-line SOL-R results remain on track for first quarter 2028.
Pravin Dugel framed 2026 as a transformational year and said the company is in the strongest position in its history. He stressed that AXPAXLI is the only intravitreal sustained-release maintenance agent with positive Phase III wet AMD data, and repeatedly tied the company’s confidence to drug potency, the hydrogel delivery system, trial design, and patient selection. His tone was highly confident and promotional about the opportunity, while emphasizing that the company is executing carefully with the FDA and preparing for potential approval and launch.
No standalone CFO prepared remarks were given, but management provided financial and capital-allocation commentary. Pravin Dugel said Ocular ended the quarter with $530.6 million in cash and cash equivalents, which management believes provides runway into 2028 based on current assumptions, excluding the full anticipated expenses of commercialization. He also said the company remains disciplined in capital allocation while continuing to invest in regulatory, clinical, and commercial priorities.
Analysts focused mainly on why SOL-X was changed from 24-week to 48-week dosing, why SOL-R’s endpoint was moved to week 40, and whether the company had spoken with the FDA about those changes. Management said the changes were aligned with regulators and were meant to protect trial integrity, avoid operational bias, and better reflect confidence in AXPAXLI’s durability. They also said the NDA will use only SOL-R week 52 safety data, not efficacy, and that they do not expect SOL-R efficacy to be required for U.S. approval. Questions about repeat dosing were answered by noting that all patients in SOL-1 at week 52 underwent repeat dosing and that the company will submit more than 300 patients with repeat-dose exposure in the safety package.
The bull case from this call is that Ocular believes it has unusually strong Phase III wet AMD data and a clearer regulatory path than before, with NDA filing still targeted for the fourth quarter. Management also pointed to durable post-hoc results, a widened commercial story around annual maintenance dosing, and early payer engagement covering roughly 84% of commercial lives.
The main risk discussed was execution around the regulatory package and preserving SOL-R integrity while advancing the NDA, including the possibility that the company is relying on a single-trial U.S. approval path. The broader commercialization story also depends on proving real-world uptake for a novel maintenance paradigm in a market where bolus anti-VEGF therapies are already established, and the company is still awaiting key future data from SOL-R and HELIOS-3.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.1%
- Shares Outstanding
- 220.02M
- Float Shares
- 185.07M
of shares held by institutions
277 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 33.16M | ▲ 315.99K |
| Blackrock, Inc. | 19.97M | ▲ 598.23K |
| Deep Track Capital, LP | 19.69M | 0 |
| Avoro Capital Advisors LLC | 12.54M | ▲ 225.00K |
| Summer Road LLC | 12.46M | ▲ 255.00K |
| Vanguard Group Inc | 11.58M | ▲ 2.41M |
| Venrock Adviser, LLC | 10.35M | 0 |
| Vanguard Capital Management LLC | 8.94M | ▲ 108.46K |
| Price T Rowe Associates Inc | 7.62M | ▲ 1.73M |
| State Street Corp | 5.58M | ▲ 342.17K |
| Logos Global Management LP | 5.30M | ▲ 1.45M |
| Geode Capital Management, LLC | 5.27M | ▲ 252.05K |
Held by 252 ETFs
Biggest fund positions in OCUL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Sherif Riad | other | 88,000 |
| Nov 6, 26 | Sherif Riad | other | 28,000 |
| Nov 6, 26 | Sherif Riad | other | 0 |
| Nov 5, 26 | Saroj Namrata | sell | 35,370 |
| Oct 8, 26 | Anderman Todd | sell | 11,984 |
| Oct 2, 26 | Kaiser Peter | sell | 9,990 |
| Oct 2, 26 | Heier Jeffrey S. | sell | 10,869 |
| Aug 31, 26 | Notman Donald | sell | 1,099 |
| Aug 24, 26 | Kaiser Peter | sell | 3,035 |
| Aug 24, 26 | Nayak Sanjay | sell | 1,897 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OCUL coverage
Recent articles, reports, and earnings notes.
No research on OCUL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCUL report →Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 20
Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Ocular: Maintaining 'Buy' On AXPAXLI NDA Submission Q4 2026 And DR Expansion Possibility
seekingalpha.com · Nov 13
Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 9
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com · Nov 9
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.